HPGD Recombinant Monoclonal Antibody

說明書

中文名稱：

HPGD Recombinant Monoclonal Antibody
貨號：

CSB-RA914804A0HU
規格：

￥1320
圖片：
Western Blot
Positive WB detected in: A549 whole cell lysate(30μg)
All lanes: HPGD antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/40000 dilution
Predicted band size: 29 kDa
Observed band size: 29 kDa
Exposure time：1min

Overlay Peak curve showing PC-3 cells stained with CSB-RA914804A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for?10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P15428
基因名：

HPGD
別名：

15-hydroxyprostaglandin dehydrogenase [NAD(+)] (15-PGDH) (EC 1.1.1.141) (Prostaglandin dehydrogenase 1) (Short chain dehydrogenase/reductase family 36C member 1), HPGD, PGDH1 SDR36C1
反應種屬：

Human
免疫原：

A synthesized peptide from human HPGD protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

6H5
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, FC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
FC	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Primary enzyme catalyzing the conversion of hydroxylated arachidonic acid species to their corresponding oxidized metabolites (Probable). Prostaglandin inactivation, catalyzes the first step in the catabolic pathway of the prostaglandins. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Converts 11(R)-HETE to 11-oxo-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid (ETE). Has hydroxylated docosahexaenoic acid metabolites as substrates. Converts resolvins E1, D1 and D2 to their oxo products which represents a mode of resolvins inactivation and stabilizes their anti-inflammatory actions.
基因功能參考文獻：
1. Higher enzyme levels of 15-PGDH exist in the lumen of intracranial aneurysms of men compared with women. This observation could explain why aspirin confers better protection against IA rupture in men than in women. PMID: 29042428
2. HPGD expression in colorectal cancer and its role in cetuximab resistance PMID: 28320945
3. Results found that low 15-PGDH expression was significantly associated with advanced tumors, presence of lymph node metastasis and invasion, and poor prognosis in pancreatic ductal adenocarcinoma patients. PMID: 29224225
4. The reduced 15-PGDH may result in PGE2 accumulation which sustains carcinogenesis and tumor progression. We further found that miR-21 exert its oncogenic role through PGE2/PI3K/Akt/Wnt/beta-catenin axis in gastric cell proliferation. In conclusion, our findings enlarged our knowledge in the roles of miR-21 in the progression of gastric cancer. PMID: 29101039
5. WNT5A signaling regulates 15-PGDH expression. PMID: 27522468
6. miR-21-HPGD regulatory module may play an important role as part of a feed-forward loop that regulates the PGE2 signaling. Such a feed-forward regulatory mechanism likely plays a critical role in OTSCC initiation and progression. PMID: 27561985
7. inhibitory effects of 17-AAG on PGE2 levels in HT-29 colorectal cancer cells were mediated through modulating COX-2 and 15-PGDH expression. PMID: 27075590
8. A common mutation and a novel mutation in HPGD gene were identified to be responsible for primary hypertrophic osteoarthropathy PMID: 26135126
9. Peroxisome proliferator-activated receptors (PPARs) play pivotal roles in maintenance of Chorionic NAD-dependent 15-hydroxy prostaglandin dehydrogenase (PGDH) expression in chorion during human pregnancy. PMID: 26093984
10. Neoadjuvant chemotherapy could increase 15-PGDH expression in advanced gastric cancer patients, and 15-PGDH may serve as a candidate prognostic biomarker of advanced GC response to therapy. PMID: 26261578
11. 15-PGDH mRNA levels were significantly higher in aorta samples from patients undergoing abdominal aortic aneurysm repair than in those from healthy multiorgan donors. PMID: 26287481
12. a homozygous 2-bp deletion (c.310_311delCT or p.L104AfsX3) was identified two primary hypertrophic osteoarthropathy siblings PMID: 24533558
13. Omega-3 polyunsaturated fatty acids upregulate the expression of 15-PGDH by inhibiting miR-26a and miR-26b. PMID: 25691459
14. Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. PMID: 25433169
15. Loss of PGDH expression is associated with esophageal squamous cell carcinoma and adenocarcinoma. PMID: 25735395
16. A single nucleotide polymorphism in the 3' untranslated region (UTR) of the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene modifies mir-485-5p binding in breast cancer. PMID: 25003827
17. Case Reports: novel 2-bp homozygous deletion was found in exon 3 (c.310-311delCT) of HPGD gene in the patients with Primary hypertrophic osteoarthropathy. PMID: 24816859
18. Tissues from 15-PGDH knockout mice demonstrate similar increased regenerative capacity. PMID: 26068857
19. Hypertrophic osteoarthropathy in the Chinese family is caused by a homozygous mutation (c.310_311delCT) in the HPGD gene. PMID: 25863089
20. Data show that hydroxylated Omega-3 fatty acid species are conferred with cell signaling capabilities after oxidation by 15-Hydroxyprostaglandin dehydrogenase (15PGDH). PMID: 25586183
21. these findings suggest that 15 d-PGJ2 induces the expression of 15-PGDH through ROS-mediated activation of ERK1/2 and subsequently Elk-1 in the MDA-MB-231 cells PMID: 25773924
22. Cholangiocarcinogenesis and tumor progression are regulated by a novel interplay between COX-2/PGE2 and miR-21 signaling, which converges at 15-PGDH. PMID: 24699315
23. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development. PMID: 24694755
24. 15-PGDH expression level in normal colon mucosa may serve as a biomarker that may predict stronger benefit from aspirin chemoprevention. PMID: 24760190
25. 15-PGDH/15-KETE stimulates the cell cycle progression and proliferation of pulmonary arterial smooth muscle cells involving ERK1/2-mediated PAR-2 expression, and contributes to hypoxia-induced pulmonary vascular remodeling. PMID: 24657469
26. 15-PGDH is downregulated in human hepatoma cells with a high COX-2 expression, in chemical and genetic murine models of hepatocellular carcinoma (HCC) and in human HCC biopsies. PMID: 23954207
27. The 15-PGDH gene is a MiTF-CX target gene in cervical stromal cells and is down-regulated by PGE2 through EP2 receptors. PMID: 24471568
28. The T allele showed increased cancer risk and decreased 15-PGDH expression. PMID: 23717544
29. Decreased PGDH expression is associated with increased GR and PRA, although decreased PRB, in chorion during labor. PMID: 23506845
30. Colonic 15-PGDH levels are highly reproducible within individuals and stable along the length of the colon PMID: 23625286
31. H. pylori appeared to promote gastric carcinogenesis by suppressing 15-PGDH. PMID: 23430757
32. beta-catenin has a novel role in promoting colorectal tumorigenesis through very early 15-PGDH suppression leading to increased PGE(2) levels, possibly even before COX-2 upregulation. PMID: 22082586
33. protein tyrosine nitration of 15-hydroxy prostaglandin dehydrogenase in the human mast cells PMID: 22197745
34. Data suggest that reduction of 15-PGDH is associated with carcinogenesis and development of gastric carcinoma. PMID: 22416177
35. Our results indicate that HPGD is highly expressed in metastatic and aggressive breast cancer and promotes epithelial-mesenchymal transition and migration in breast cancer cells. PMID: 22072156
36. clinical and biochemical data of three unrelated primary hypertrophic osteoarthropathy families with HPGD mutations; evidence that c.175_176del is a recurrent mutation rather than an ancient founder allele PMID: 21426412
37. Report homozygous mutations in the 15-hydroxyprostaglandin dehydrogenase gene in patients with primary hypertrophic osteoarthropathy. PMID: 19306095
38. Results demonstrate that 15-PGDH acts as a tumor suppressor in gastric cancer and provide further validation for 15-PGDH as a potential therapeutic target for gastric cancer. PMID: 20699658
39. Demonstrate both downregulation and a tumor suppressor activity of 15-PGDH in gastric cancer. PMID: 21469975
40. The PLA2G7, HPGD, EPHX2, and CYP4F8 genes are highly expressed in prostate cancer. PMID: 21281786
41. The c.175_176delCT frameshift mutation appears to be recurrent and to be the commonest HPGD mutation in Caucasian families with primary hypertrophic osteoarthropathy. PMID: 20299379
42. Data show that the Vmax for the oxidation of PGE2 was 28.1 micromol/(min.mg), and the catalytic constant, kcat, was about 14 per second; the catalytic efficiency, kcat/Km, was 2.5.106. PMID: 21072165
43. our data do not support the previously reported associations of HPGD tagSNPs and risk of colorectal cancer. PMID: 21047993
44. Reduced expression of 15-PGDH contributes to the elevated levels of PGs found in the skin following UVR exposure. PMID: 20643784
45. The study shows that cPLA2 and mPGES-1, in addition to COX-2, are constitutively overexpressed, and that 15-PGDH might be attenuated in colorectal cancer. Furthermore, cPLA2 and 15-PGDH as well as COX-2 could have an important role in tumor progression. PMID: 20635443
46. analysis of expression of serum vitamin D receptor, cyclooxygenase-2, and 15-hydroxyprostaglandin dehydrogenase in benign and malignant ovarian tissue and 25-hydroxycholecalciferol and prostaglandin E2 in ovarian cancer patients PMID: 20304053
47. These results suggest that enhanced PGE2 production proceeds through the expressions of COX-2 and microsomal PGES-1 and down-regulation of PGDH by SNAI2 in pancreatic tumors. PMID: 19820419
48. Loss of PGDH expression contributes to a more malignant bladder cancer phenotype and may be necessary for bladder cancer development and/or progression. PMID: 20093479
49. Genetic variants in HPGD encoding 15-PGDH, appear to modulate colorectal risk. The present study appears to be the first to evaluate possible associations between genetic heterogeneity in HPGD and CRC risk. PMID: 20042636
50. reduction of 15-PGDH is an independent predictor of poor survival associated with enhancement of cell proliferation in gastric adenocarcinoma. PMID: 19917058
顯示更多

收起更多
相關疾病：

Hypertrophic osteoarthropathy, primary, autosomal recessive, 1 (PHOAR1); Cranioosteoarthropathy (COA); Isolated congenital nail clubbing (ICNC)
亞細胞定位：

Cytoplasm.
蛋白家族：

Short-chain dehydrogenases/reductases (SDR) family
組織特異性：

Detected in colon epithelium (at protein level).
數據庫鏈接：

HGNC: 5154

OMIM: 119900

KEGG: hsa:3248

STRING: 9606.ENSP00000296522

UniGene: Hs.596913

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human